Title : ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.

Pub. Date : 2020

PMID : 33093947






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Discussion: ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL. acalabrutinib keratin 20 Homo sapiens